SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, officially announced today the recent incorporation of CoSara Diagnostics, Pvt., Ltd., a Joint Venture for manufacturing with Synbiotics Limited. Synbiotics is a group company of Asence Inc, a U.S. incorporated company specializing in supplying pharmaceutical products to international markets.

Co-Diagnostics and Synbiotics incorporated the CoSara entity in India in July. Co-Diagnostics paid for its commitment to CoSara from its recent initial public offering. CoSara intends to secure all applicable regulatory approvals necessary for allowing the sale and distribution of CoSara-branded diagnostics throughout India, with a manufacturing facility expected to be under construction in Q3 2017. Once completed, CoSara will have the exclusive Indian manufacturing rights for Co-Diagnostics products.

Dwight Egan, Co-Diagnostics CEO, commented, “India has been a focal point of our growth plan for several years, and partnering with an outstanding organization such as Synbiotics for in-country manufacturing moves us significantly closer to realizing those goals. Because India has an estimated 400 million cases of tuberculosis from which there are 1,000 deaths each day, it is the ideal market for launching a high-quality, affordable test that can not only have a positive impact on the affected population, but also help to build a strong customer base for our other diagnostic products already in the pipeline.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer:

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts
Co-Diagnostics, Inc.
Investor Relations, 801-438-1036
investors@codiagnostics.com